Paragon Sports Medicine

Home/ Peptides/ NAD+

BAck to all peptides

NAD+ (Nicotinamide Adenine Dinucleotide)

Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme present in all living cells, serving as a critical cofactor in cellular energy metabolism, DNA repair mechanisms, and cellular signaling pathways. As a key participant in oxidative phosphorylation, NAD+ facilitates the conversion of nutrients into adenosine triphosphate (ATP), the primary cellular energy currency.

This coenzyme has gained considerable attention in longevity medicine due to its demonstrated roles in mitochondrial function, sirtuin activation, and cellular repair processes. NAD+ participates in over 400 enzymatic reactions throughout the human body and exhibits age-related decline that correlates with mitochondrial dysfunction, metabolic disorders, and neurodegenerative diseases.

Molecular structure diagram of a peptide chain showing connected amino acids with amino, carboxyl, and side groups.

Overview

NAD+ exists in two primary forms: NAD+ (oxidized) and NADH (reduced), with the NAD+/NADH ratio serving as a critical indicator of cellular metabolic state and energy availability. The coenzyme is highly water-soluble and suitable for various administration routes, though it demonstrates poor oral bioavailability.

Patient consulting with Dr. Ched Garten at Paragon, symbolizing advanced non-surgical care for joint, tendon, muscle, and pain issues.

Chemical structure & Properties

  • Molecular Formula: C21H27N7O14P2
  • Molecular Weight: 663.43 Da
  • Sequence: Dinucleotide composed of adenosine and nicotinamide ribonucleotides
  • Half-life: Variable (minutes to hours depending on tissue and metabolic state)
  • Stability: Sensitive to light and heat, requires careful storage conditions

Mechanism of Action

NAD+ exerts its therapeutic effects through multiple interconnected molecular pathways:

Energy Metabolism

NAD+ serves as a critical electron acceptor in cellular respiration, facilitating:

  • Enhanced ATP synthesis through oxidative phosphorylation
  • Improved mitochondrial function and biogenesis
  • Increased cellular energy availability
  • Optimization of metabolic efficiency

DNA Repair Mechanisms

The coenzyme supports genomic stability through:

  • Serving as substrate for poly(ADP-ribose) polymerases (PARPs)
  • Facilitating DNA damage detection and repair
  • Maintaining chromosomal integrity
  • Supporting cellular stress response pathways

Sirtuin Activation

NAD+ activates longevity pathways by:

  • Serving as essential cofactor for sirtuins (SIRT1-7)
  • Promoting NAD+-dependent deacetylase activity
  • Regulating gene expression related to aging
  • Enhancing cellular stress resistance mechanisms

Cellular Signaling

The coenzyme influences cellular communication through:

  • Participation in cyclic ADP-ribose (cADPR) synthesis
  • Modulation of calcium signaling pathways
  • Support of neurotransmission processes
  • Enhancement of muscle contraction mechanisms

Areas Investigated in

the Research Literature

Patient consulting with Dr. Ched Garten at Paragon, symbolizing advanced non-surgical care for joint, tendon, muscle, and pain issues.

Current Clinical Evidence

Safety Profile and Considerations

Clinical Safety Data

Human studies across multiple administration routes demonstrate:

  • Generally well tolerated in supervised use.
  • Long-term/high-dose protocol data are limited, and adverse effects vary by route and infusion rate.
  • No significant organ toxicity reported
  • Safe administration across age groups

Potential Concerns

Theoretical Considerations:

  • Enhanced cellular energy may theoretically support malignant cell growth
  • Limited long-term safety data for high-dose protocols
  • Potential interactions with certain medications

Administration-Specific Effects:

  • Mild injection site reactions (subcutaneous)
  • IV NAD+ can cause a flushing/rushing sensation; slow infusion is used to improve tolerability.
  • Occasional nasal irritation (intranasal)

Contraindications

NAD+ should be used with caution in:

  • Active malignancy (theoretical energy enhancement concern)
  • Pregnancy and breastfeeding (insufficient safety data)
  • Severe cardiovascular instability (monitor during high-dose protocols)
  • Known hypersensitivity to NAD+ or related compounds

Regulatory Status and Legal Considerations

Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.

FDA Status

  • Classification: NAD+ is not FDA-approved as a pharmaceutical agent for specific therapeutic indications
  • Approval Status: Not approved as pharmaceutical agent for specific therapeutic indications
  • Clinical Use: Available for clinical administration under healthcare provider supervision
  • Regulatory Position: Accepted for use in clinical and wellness applications

WADA Status

  • WADA: NAD+ is not on the WADA Prohibited List and is not a prohibited substance.

Legal Availability

  • Commercial Status: Not approved as a pharmaceutical for a specific disease. Availability varies by formulation and by current compounding rules.
  • Market Presence: Available as injectable formulations and oral supplements
  • Quality Control: Variable quality standards across suppliers
  • Clinical Use: Widely used in integrative and longevity medicine practices
Man seated indoors with a soccer ball in natural light, representing Paragon’s musculoskeletal recovery expertise and regenerative treatment focus.

Conclusion

What the evidence supports is NAD+ is a coenzyme central to energy metabolism, DNA repair, and sirtuin signaling. Preclinical work has reported improved mitochondrial function and glucose tolerance, and early human trials of NAD+ precursors have reported changes in blood NAD+ levels. Clinical outcome data in humans remains limited, trials are small, and optimal dosing has not been established. NAD+ is not FDA approved as a treatment for any age-related condition. This page summarizes the published research and nothing further.

NAD+ SCIENTIFIC

DATA SUMMARY

MOLECULAR CHARACTERISTICS
PRECLINICAL EFFICACY DATA
CLINICAL EVIDENCE SUMMARY
SAFETY PROFILE
REGULATORY STATUS
Parameter
Molecular Weight
Amino Acid Length
Half-Life
Bioavailability
Detection Window
Value
663.4 Da
C21H27N7O14P2
Variable (tissue-dependent)
Poor oral absorption
Cytoplasm, mitochondria, nucleus
Application
Metabolic Function
Aging/Longevity
Neuroprotection
Cardiovascular
Reported outcome (model)
Improved glucose tolerance, enhanced mitochondrial function
Extended lifespan, improved healthspan markers
Reduced neurodegeneration, improved cognitive function
Enhanced cardiac function, improved vascular health
Study Type
Phase I Safety
Metabolic Studies
Aging Pilot
Exercise Performance
Population
Healthy adults
Adults with metabolic syndrome
Elderly volunteers
Athletes/Active adults
Results
Generally well tolerated
Improved insulin sensitivity
Enhanced cellular energy markers
Mixed results on performance
Limitations
Small sample sizes
Short-term studies only
Limited clinical endpoints
Varied protocols, small studies
Parameter
Acute Toxicity
Chronic Toxicity
Common Side Effects
Drug Interactions
Contraindications
Finding
Low toxicity (>2000 mg/kg in animal studies)
No significant adverse effects in long-term studies
Mild GI upset, flushing (at high doses)
Potential interactions with diabetes medications
Pregnancy, breastfeeding (insufficient data)
Authority
FDA
EFSA
Health Canada
TGA (Australia)
Classification
Dietary Supplement
Novel Food Assessment
Natural Health Product
Listed Medicine
Status
No FDA GRAS designation; sold as a supplement ingredient
Under evaluation
Licensed for specific claims
Approved for therapeutic use

About this library

This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.

This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.

Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. Patients should consult with qualified healthcare providers before beginning any NAD+ therapy.

Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.

References

01
NAD+ in aging, metabolism, and neurodegeneration. Science. 2015.
02
NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014.
03
Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022.
04
The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023.
05
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. Adv Nutr. 2023.
06
Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2023.